EP Global Communications, Inc . (EPGL), (the Company), (Pink Sheets: EPGL), ( www.eparent.com), the parent company of Exceptional Parent ( EP) magazine, and the EP Health Sciences Division are announcing to investors that on the eve of this year’s World Conference on Disabilities (WCD), the Muscle Pain Detection Device (MPDD) has been evaluated at two major US health institutions with several more expressing interest. “Evaluation results are positive and we anticipate the FDA approved device, coupled with Dr. Norman Marcus’ treatment protocol, will help many millions of people impacted by pain,” said Joseph M. Valenzano Jr., CEO of EP Global Communications, Inc. “Use of the MPDD can provide clinicians with information about which muscles are causing back and neck pain and help reduce the associated staggering direct medical costs - 86 billion in 2005. It just needs more awareness, which we hope to help provide.” This announcement comes as EP Global Communications is seeing unprecedented events and developments in its 40-year history. “We are excited about recent financial restructuring agreements as well as contracts and affiliations, including those with Web MD, the United States Marine Corps and soon the US Army, and a Keynote Address by Admiral Michael Mullen, Chairman of the Joint Chiefs of Staff, to kick off this year’s World Conference on Disabilities in Dallas, Texas,” explained Valenzano. In addition, several online educational seminars will be broadcast live on the internet free of charge and investors, subscribers, and readers are encouraged to register and attend. Among the seminars to be broadcast is the presentation by Dr. Marcus to conference attendees and those viewing live online worldwide on how a muscle evaluation and treatment protocol utilizing the MPDD can reduce disability related to neck and back pain. Other seminars such as new treatment therapies for epilepsy, including surgical interventions, will also be available.
EPGL Fact Sheet for InvestorsAs previously announced, EP Global Communications has an agreement for a major financial restructuring with its debt holders and will be presenting this to shareholders shortly. This agreement will see EP’s major creditors convert more than one half of the company’s debt into equity. This will result in a significantly improved balance sheet for EP and will fully align the interests of debt holders with shareholders. Because of EPGL’s unique position in the healthcare industry and nexus of companies, scientists, caregivers and major health care institutions, the Company is able to bring together the best and the brightest minds to achieve its objective of developing, translating and sharing information as tools for positive change for the special needs community. As an example of this nexus, EP maintains strong strategic relationships with virtually every major consumer association and organization, and several professional medical societies serving those with disabilities in the nation including the US Military. In the area of pharmaceutical science, EP has established and enjoys strong relationships with the following major companies: Pfizer Allergan Cyberonics Medtronic Neurologicals Shire USA Medpointe Pharmaceuticals Valeant Pharmaceuticals UCB Pharma Eli Lilly Novartis Ross Labs Mead Johnson Read the continuation of this press release and a complete listing of all EP Partners in the health care industry at www.eparent.com under the Investor Relations Channel. About EP Global Communications, Inc. EP Global Communications, Inc., parent company of Exceptional Parent ( EP) magazine, is a 40-year-old, award-winning, multi-media publishing and communications company, providing timely and indispensable resources and information to families and professionals caring for the needs of children and adults with disabilities and special health care needs, including families in the U.S. Military. Safe Harbor Statement Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.